MY150820A - Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance - Google Patents
Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substanceInfo
- Publication number
- MY150820A MY150820A MYPI20102785A MY150820A MY 150820 A MY150820 A MY 150820A MY PI20102785 A MYPI20102785 A MY PI20102785A MY 150820 A MY150820 A MY 150820A
- Authority
- MY
- Malaysia
- Prior art keywords
- salt
- methyl ester
- acid methyl
- cysteic acid
- water soluble
- Prior art date
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title abstract 3
- 239000013543 active substance Substances 0.000 title abstract 2
- 238000012377 drug delivery Methods 0.000 title abstract 2
- 125000002091 cationic group Chemical group 0.000 title 1
- -1 CYSTEIC ACID METHYL ESTER Chemical class 0.000 abstract 6
- XVOYSCVBGLVSOL-UHFFFAOYSA-N L-cysteine sulfonic acid Natural products OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 abstract 6
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 239000002245 particle Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SE2007/001128 WO2009078755A1 (en) | 2007-12-19 | 2007-12-19 | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY150820A true MY150820A (en) | 2014-02-28 |
Family
ID=40795733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20102785 MY150820A (en) | 2007-12-19 | 2008-12-18 | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8324274B2 (OSRAM) |
| EP (1) | EP2231193B1 (OSRAM) |
| JP (1) | JP5466174B2 (OSRAM) |
| KR (1) | KR101616135B1 (OSRAM) |
| CN (1) | CN101945671B (OSRAM) |
| AU (1) | AU2008339101B2 (OSRAM) |
| BR (1) | BRPI0821739B8 (OSRAM) |
| CA (1) | CA2709268C (OSRAM) |
| CY (1) | CY1121145T1 (OSRAM) |
| DK (1) | DK2231193T3 (OSRAM) |
| EA (1) | EA018559B1 (OSRAM) |
| ES (1) | ES2689509T3 (OSRAM) |
| HR (1) | HRP20181517T1 (OSRAM) |
| HU (1) | HUE039695T2 (OSRAM) |
| LT (1) | LT2231193T (OSRAM) |
| MX (1) | MX2010006906A (OSRAM) |
| MY (1) | MY150820A (OSRAM) |
| NZ (1) | NZ586858A (OSRAM) |
| PL (1) | PL2231193T3 (OSRAM) |
| PT (1) | PT2231193T (OSRAM) |
| SI (1) | SI2231193T1 (OSRAM) |
| WO (2) | WO2009078755A1 (OSRAM) |
| ZA (1) | ZA201004992B (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009078756A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
| WO2009078754A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
| CN112239418B (zh) * | 2019-07-18 | 2023-07-07 | 上海现代药物制剂工程研究中心有限公司 | 视黄醇类化合物及其钠盐的制备方法 |
| CN112321465B (zh) * | 2019-07-18 | 2023-06-06 | 上海现代药物制剂工程研究中心有限公司 | 一种含苯基化合物、其中间体、制备方法及应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197809B1 (en) * | 1998-12-23 | 2001-03-06 | Ardenia Investments Ltd. | Compounds for the treatment of cancer |
| JP4643009B2 (ja) * | 1999-03-11 | 2011-03-02 | アーデニア・インベストメンツ・リミテッド | 癌治療のための新規化合物 |
| US6656504B1 (en) | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
| SE0101702D0 (sv) * | 2001-05-15 | 2001-05-15 | Ardenia Investments Ltd | Novel potentiating compounds |
| KR100566911B1 (ko) * | 2001-06-25 | 2006-04-03 | 주식회사 삼양사 | 약물 전달체용 음이온기-함유 양친성 블록 공중합체 및 그의 양이온성 약물과의 복합체 |
| US20050191359A1 (en) * | 2001-09-28 | 2005-09-01 | Solubest Ltd. | Water soluble nanoparticles and method for their production |
| US20050249786A1 (en) * | 2001-09-28 | 2005-11-10 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds |
| JP2004010479A (ja) * | 2002-06-03 | 2004-01-15 | Japan Science & Technology Corp | ブロック共重合体とアンスラサイクリン系抗癌剤を含む新規固型製剤及びその製造法 |
| SE0202311D0 (sv) * | 2002-07-23 | 2002-07-23 | Ardenia Investments Ltd | Novel compounds, cytotoxic preparations comprising said compounds, methods of manufacture of said preparations, as well as methods of treatment |
| JP2006199590A (ja) * | 2003-09-04 | 2006-08-03 | Nano Career Kk | 水溶性の塩基性薬物内包ナノ粒子含有組成物 |
| US20050196343A1 (en) * | 2004-02-27 | 2005-09-08 | Molecular Therapeutics, Inc. | Degradable nanoparticles |
| US8945629B2 (en) * | 2004-09-10 | 2015-02-03 | University Of Wyoming | Nanoparticles for cytoplasmic drug delivery to cancer cells |
| CA2598239C (en) * | 2005-02-18 | 2019-10-29 | Abraxis Bioscience, Inc. | Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy |
| AU2006284657B2 (en) * | 2005-08-31 | 2012-07-19 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| WO2009078754A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
| WO2009078756A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
-
2007
- 2007-12-19 WO PCT/SE2007/001128 patent/WO2009078755A1/en not_active Ceased
-
2008
- 2008-12-18 HU HUE08863195A patent/HUE039695T2/hu unknown
- 2008-12-18 HR HRP20181517TT patent/HRP20181517T1/hr unknown
- 2008-12-18 KR KR1020107015634A patent/KR101616135B1/ko active Active
- 2008-12-18 JP JP2010539387A patent/JP5466174B2/ja not_active Expired - Fee Related
- 2008-12-18 ES ES08863195.7T patent/ES2689509T3/es active Active
- 2008-12-18 EA EA201070626A patent/EA018559B1/ru unknown
- 2008-12-18 CA CA2709268A patent/CA2709268C/en active Active
- 2008-12-18 MY MYPI20102785 patent/MY150820A/en unknown
- 2008-12-18 NZ NZ586858A patent/NZ586858A/en not_active IP Right Cessation
- 2008-12-18 PL PL08863195T patent/PL2231193T3/pl unknown
- 2008-12-18 MX MX2010006906A patent/MX2010006906A/es active IP Right Grant
- 2008-12-18 AU AU2008339101A patent/AU2008339101B2/en not_active Ceased
- 2008-12-18 EP EP08863195.7A patent/EP2231193B1/en active Active
- 2008-12-18 WO PCT/SE2008/051517 patent/WO2009078804A1/en not_active Ceased
- 2008-12-18 DK DK08863195.7T patent/DK2231193T3/en active
- 2008-12-18 US US12/809,265 patent/US8324274B2/en active Active
- 2008-12-18 CN CN2008801270941A patent/CN101945671B/zh not_active Expired - Fee Related
- 2008-12-18 BR BRPI0821739A patent/BRPI0821739B8/pt not_active IP Right Cessation
- 2008-12-18 SI SI200831998T patent/SI2231193T1/sl unknown
- 2008-12-18 LT LTEP08863195.7T patent/LT2231193T/lt unknown
- 2008-12-18 PT PT08863195T patent/PT2231193T/pt unknown
-
2010
- 2010-07-14 ZA ZA2010/04992A patent/ZA201004992B/en unknown
-
2018
- 2018-10-03 CY CY20181101023T patent/CY1121145T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Varghese et al. | Cubosomes in cancer drug delivery: A review | |
| Ahmed et al. | Development of an optimized avanafil-loaded invasomal transdermal film: Ex vivo skin permeation and in vivo evaluation | |
| Ghori et al. | Nasal drug delivery systems: An overview | |
| Khatoon et al. | Proniosomes derived niosomes: recent advancements in drug delivery and targeting | |
| Guan et al. | N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy | |
| Illum | Nasal drug delivery—Recent developments and future prospects | |
| Ji et al. | Targeted therapy of SMMC-7721 liver cancer in vitro and in vivo with carbon nanotubes based drug delivery system | |
| Li et al. | A cell-penetrating peptide mediated chitosan nanocarriers for improving intestinal insulin delivery | |
| MY157187A (en) | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance | |
| GB0814302D0 (en) | Compounds and methods | |
| JP7568185B2 (ja) | アミノ酸ベースの栄養素の使用及びそれを含む医薬組成物 | |
| MX2009012279A (es) | Distribucion de micro y nanoparticulas con plaquetas. | |
| WO2007040469A3 (en) | Chloroquine coupled compositions and methods for their synthesis | |
| An et al. | Recent advancements and trends of topical drug delivery systems in psoriasis: a review and bibliometric analysis | |
| CY1121145T1 (el) | Συστημα χορηγησης φαρμακων για χορηγηση μιας υδατοδιαλυτης, κατιοντικης και αμφιφιλης φαρμακευτικως ενεργης ουσιας | |
| CN104323985B (zh) | 一种基于碳材料的多糖类口服结肠靶向水凝胶的制备方法与应用 | |
| Chang et al. | Sonication-assisted self-assembled resveratrol nanoparticles with enhanced antiviral and anti-inflammatory activity against respiratory syncytial virus-induced pneumonia | |
| BRPI0821741B8 (pt) | sistema de liberação de droga para administração de uma substância anfifílica catiônica farmaceuticamente ativa compreendendo nanopartículas, composição farmacêutica, método de preparação de composição farmacêutica e seu uso | |
| Elmowafy et al. | Polysaccharide-based platforms for nasal delivery: design, features, and perspectives | |
| CN115916142A (zh) | 偶联萜烯缀合物 | |
| Li et al. | Cysteine-modified PEGylated nanoparticles for targeted delivery of methylprednisolone to pancreatitis | |
| Jain et al. | Phospholipid Complex-based Topical Gel for Codelivery of Erlotinib and Methotrexate in Psoriasis | |
| Masoomzadeh et al. | Different ways to enhance the permeability, lipophilicity, and bioavailability of the antidiabetic drug, Metformin | |
| Jon et al. | Recent Advances in Donepezil Delivery Systems via the Nose-to-Brain Pathway | |
| CN114010592B (zh) | 一种可瘤内或瘤周注射的咪喹莫特混悬液制剂及其制备方法和应用 |